Comparing Octreotide vs Sandostatin
| Octreotide | Sandostatin (octreotide) |
|
|---|
| Octreotide | Sandostatin (octreotide) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Carcinoid Tumor, Diarrhea, Acromegaly, Diabetes - Type 1, Vasoactive Intestinal Peptide Tumor, Dumping Syndrome, Gastrinoma, Glucagonoma, Insulinoma, Pituitary Adenoma, Postural... View more |
Prescription only
Prescribed for Carcinoid Tumor, Acromegaly, Vasoactive Intestinal Peptide Tumor. Sandostatin may also be used for purposes not listed in this medication guide. |
Related suggestions Carcinoid Tumor
Vasoactive Intestinal Peptide Tumor
Popular comparisons
|
|||||||||||||||
| More about Octreotide | More about Sandostatin (octreotide) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Octreotide has an average rating of 7.7 out of 10 from a total of 18 ratings on Drugs.com. 72% of reviewers reported a positive effect, while 11% reported a negative effect. |
Sandostatin has an average rating of 8.0 out of 10 from a total of 7 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Octreotide side effects |
View all Sandostatin side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
Lower cost generic |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Octreotide prices |
View all Sandostatin prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin LAR Depot | Other octreotide brands include: Bynfezia Pen, Mycapssa, Sandostatin LAR Depot | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
1.5 hours |
1.5 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 167 drugs are known to interact with Octreotide:
|
A total of 167 drugs are known to interact with Sandostatin:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
June 26, 2020 |
October 21, 1988 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.